Tandem Diabetes Care | TNDM - Current Assets


Tandem Diabetes Care reported $887.1M in Current Assets for its fiscal quarter ending in March of 2026.





Current Assets Change Date
Abbott USD 25.51B 488M Mar/2026
Accuray USD 292.39M 11.22M Dec/2025
Align Technology USD 2.66B 38.87M Mar/2026
AtriCure USD 313.69M 8.82M Mar/2026
Baxter International USD 6.85B 25M Mar/2026
Becton, Dickinson and Co. USD 8.01B 1.18B Mar/2026
Boston Scientific USD 8.68B 110M Mar/2026
Cooper Companies USD 2.3B 166M Mar/2026
Dexcom USD 4.33B 298.4M Mar/2026
Edwards Lifesciences USD 6.23B 510.2M Mar/2026
Eli Lilly USD 54.84B 794M Mar/2026
Globus Medical USD 2.2B 72.51M Mar/2026
ICU Medical USD 1.21B 22.69M Mar/2026
Inogen USD 203.72M 594K Sep/2025
Insulet USD 1.71B 204.5M Mar/2026
Integra LifeSciences USD 1.17B 12.47M Mar/2026
Intuitive Surgical USD 11.52B 881.5M Mar/2026
J&J USD 59.17B 3.55B Mar/2026
Medtronic USD 24.07B 75M Dec/2025
Merit Medical Systems USD 1.1B 61.62M Mar/2026
Orthofix International USD 461.52M 44.67M Mar/2026
Roche Holding CHF 38.73B 3.03B Dec/2025
Stryker USD 13.34B 1.42B Mar/2026
Tandem Diabetes Care USD 887.1M 268.96M Mar/2026
Teleflex USD 1.86B 78.67M Mar/2026
Zimmer Biomet Holdings USD 4.96B 157.4M Mar/2026